These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 21095449

  • 1. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [Abstract] [Full Text] [Related]

  • 2. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 3. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 4. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 5. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Nov; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 6. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [Abstract] [Full Text] [Related]

  • 7. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 8. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 9. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
    Iaria G, Anselmo A, De Luca L, Manuelli M, Lucchesi C, Tariciotti L, Monaco A, Sforza D, Nigro F, Abruzzese E, Tisone G.
    Transplant Proc; 2007 May; 39(6):2036-7. PubMed ID: 17692685
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A, Schlitt HJ, Geissler EK.
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [Abstract] [Full Text] [Related]

  • 11. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 12. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
    Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G.
    Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
    [Abstract] [Full Text] [Related]

  • 13. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 19. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 20. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.